← Oncology Approval Tracker

FDA DECISION ·

Rasonque

daraxonrasib · Revolution Medicines

FDA approvalNew therapyPancreatic cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with metastatic pancreatic adenocarcinoma who have received at least one systemic therapy or are ineligible for multiagent systemic therapy.

SUPPORTING DATA

Evidence behind the decision

Study
RASolute 302 randomized 500 patients after progression following one line to daraxonrasib or physician-choice chemotherapy.
Key result
In the overall population, median overall survival was 13.2 vs 6.7 months (hazard ratio 0.40, 95% CI, 0.30–0.53). Median progression-free survival was 7.2 vs 3.6 months.
Safety to report
FDA lists skin and soft-tissue toxicity, oral toxicity, diarrhea, gastrointestinal perforation and ILD or pneumonitis among the warnings.
Evidence limits
The randomized study enrolled patients with progression after one prior line. The label also includes adults who are ineligible for multiagent therapy.

LAMPGEN ANALYSIS

Why it matters

RASolute 302 reported a survival benefit against physician-choice chemotherapy after one prior treatment line. The approved use also includes adults ineligible for multiagent therapy, a broader group than the pivotal study enrolled.

What research teams should watch

Preserve line-of-therapy and treatment-fitness documentation. For future trials, the new option can affect the relevance of a comparator and the therapies patients receive before enrollment.

PRIMARY RECORDS

Sources